 CAMBRIDGE, Mass., Dec. 4, 2020 PRNewswire -- Blueprint Medicines Corporation NASDAQ: BPMC, a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective on December 1, 2020, the Compensation Committee of... 